Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Homology Medicines, Inc. (FIXX) A Good Stock To Buy?

Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, many investors lost money due to unpredictable events such as the sudden increase in long-term interest rates and unintended consequences of the trade war with China. Nevertheless, many of the stocks that tanked in the third quarter still sport strong fundamentals and their decline was more related to the general market sentiment rather than their individual performance and hedge funds kept their bullish stance. In this article we will find out how hedge fund sentiment to Homology Medicines, Inc. (NASDAQ:FIXX) changed recently.

Homology Medicines, Inc. (NASDAQ:FIXX) has seen a decrease in support from the world’s most elite money managers recently. Our calculations also showed that FIXX isn’t among the 30 most popular stocks among hedge funds.

In the financial world there are a large number of tools investors have at their disposal to grade stocks. A pair of the most under-the-radar tools are hedge fund and insider trading indicators. We have shown that, historically, those who follow the top picks of the best fund managers can outperform the broader indices by a solid amount. Insider Monkey’s flagship best performing hedge funds strategy returned 6.3% year to date (through December 3rd) and outperformed the market even though it draws its stock picks among small-cap stocks. This strategy also outperformed the market by 18 percentage points since its inception (see the details here). That’s why we believe hedge fund sentiment is a useful indicator that investors should pay attention to.

James Flynn Deerfield Management

We’re going to analyze the key hedge fund action surrounding Homology Medicines, Inc. (NASDAQ:FIXX).

Hedge fund activity in Homology Medicines, Inc. (NASDAQ:FIXX)

Heading into the fourth quarter of 2018, a total of 6 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of -14% from the previous quarter. The graph below displays the number of hedge funds with bullish position in FIXX over the last 13 quarters. So, let’s see which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

No of Hedge Funds FIXX Positions

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, James E. Flynn’s Deerfield Management has the number one position in Homology Medicines, Inc. (NASDAQ:FIXX), worth close to $119.5 million, comprising 4.3% of its total 13F portfolio. Sitting at the No. 2 spot is Rock Springs Capital Management, managed by Kris Jenner, Gordon Bussard, Graham McPhail, which holds a $10.7 million position; the fund has 0.4% of its 13F portfolio invested in the stock. Remaining members of the smart money with similar optimism contain Eli Casdin’s Casdin Capital, Lee Ainslie’s Maverick Capital and Jerome Pfund and Michael Sjostrom’s Sectoral Asset Management.

Since Homology Medicines, Inc. (NASDAQ:FIXX) has faced bearish sentiment from the smart money, it’s easy to see that there exists a select few hedgies who sold off their entire stakes in the third quarter. At the top of the heap, Anand Parekh’s Alyeska Investment Group sold off the biggest investment of the 700 funds monitored by Insider Monkey, worth an estimated $2 million in stock. Ken Griffin’s fund, Citadel Investment Group, also cut its stock, about $0.3 million worth. These moves are intriguing to say the least, as total hedge fund interest fell by 1 funds in the third quarter.

Let’s now take a look at hedge fund activity in other stocks – not necessarily in the same industry as Homology Medicines, Inc. (NASDAQ:FIXX) but similarly valued. These stocks are Social Capital Hedosophia Holdings Corp. (NYSE:IPOA), Carolina Financial Corporation (NASDAQ:CARO), The Manitowoc Company, Inc. (NYSE:MTW), and ORBCOMM Inc (NASDAQ:ORBC). This group of stocks’ market caps are closest to FIXX’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
IPOA 23 297371 -2
CARO 6 46311 -1
MTW 21 204427 0
ORBC 15 129651 0
Average 16.25 169440 -0.75

View table here if you experience formatting issues.

As you can see these stocks had an average of 16.25 hedge funds with bullish positions and the average amount invested in these stocks was $169 million. That figure was $146 million in FIXX’s case. Social Capital Hedosophia Holdings Corp. (NYSE:IPOA) is the most popular stock in this table. On the other hand Carolina Financial Corporation (NASDAQ:CARO) is the least popular one with only 6 bullish hedge fund positions. Compared to these stocks Homology Medicines, Inc. (NASDAQ:FIXX) is even less popular than CARO. Considering that hedge funds aren’t fond of this stock in relation to other companies analyzed in this article, it may be a good idea to analyze it in detail and understand why the smart money isn’t behind this stock. This isn’t necessarily bad news. Although it is possible that hedge funds may think the stock is overpriced and view the stock as a short candidate, they may not be very familiar with the bullish thesis. In either case more research is warranted.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...